Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability ...

Wedbush increased their Q2 2025 earnings per share estimates for SpringWorks Therapeutics in a research report issued on Wednesday, February 12th. Wedbush analyst D. Nierengarten now expects that the ...

Stock analysts at HC Wainwright dropped their FY2024 earnings per share estimates for SpringWorks Therapeutics in a research note issued on Wednesday, February 12th. HC Wainwright analyst R. Burns now ...

We recently compiled a list of the 10 Firms Begin Trading Week With Impressive Gains. In this article, we are going to take a ...

SpringWorks Therapeutics (SWTX) has announced that the U.S. Food and Drug Administration has approved Gomekli, a small molecule MEK inhibitor, ...

SpringWorks Therapeutics (SWTX) may be acquired by Merck KGaA for $77 per share, representing a potential premium of 92% ...

Daniel Pichl, the Chief People Officer of $SWTX, sold 13,750 shares of the company on 02-10-2025 for an estimated $728,997. We received data on the trade from a ...

BofA analyst Alec Stranahan raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $65 from $55 and keeps a Buy rating on the ...

$SWTX insiders have traded $SWTX stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales. We have seen ...

Wall Street expects a year-over-year increase in earnings on higher revenues when SpringWorks Therapeutics (SWTX) reports results for the quarter ended December 2024. While this widely-known ...

Germany-based Merck KGaA (OTC:MKGAF) (OTC:MKKGY) reacted to press reports and confirmed advanced discussions with SpringWorks ...